Kylo-11 / Kylonova Biopharma, Hygieia Pharmaceuticals - LARVOL DELTA

Dose-Dependent and Sustained Reduction in Lipoprotein(a) levels after single-dose of Kylo-11, a LPA-targeted Small Interfering RNA, in Healthy Volunteers: A First-in-Human Phase I Study (AHA 2025) - P1 | "Kylo-11 was well tolerated in Chinese healthy volunteers. Higher doses produced greater and more sustained reductions in serum Lp(a) levels over 48 weeks of follow-up. These findings support further investigation of Kylo-11 in patients with elevated Lp(a), with potential for administration once every 6 months or annually."

Clinical • First-in-human • P1 data • Atherosclerosis • Cardiovascular

Kylo-11-I-C01: Single-ascending Dose Study of Kylo-11 in Healthy Subjects (clinicaltrials.gov) - P1 | N=60 | Active, not recruiting | Sponsor: Kylonova (Xiamen) Biopharma co., LTD. | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular

Kylo-11-I-C01: Single-ascending Dose Study of Kylo-11 in Healthy Subjects (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Kylonova (Xiamen) Biopharma co., LTD. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular

Kylo-11-I-C01: Single-ascending Dose Study of Kylo-11 in Healthy Subjects (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Kylonova (Xiamen) Biopharma co., LTD.

New P1 trial • Cardiovascular